A phase III, randomized, multi-center, double-blind, parallel-group, placebo controlled study to evaluate the safety and efficacy of SPD476 (mesalazine) given twice daily (2.4g/day) versus SPD476 given as a single dose (4.8g/day) in subject with acute mild to moderate ulcerative colitis.

Shire Pharmaceutical Development Inc0 个研究点目标入组 255 人开始时间: 2004年7月1日最近更新: 2023年11月6日

适应症

试验速览

暂无简介。

•- Adults aged 18 and over, male and female
•-Women of childbearing potential must use an effective contraceptive method while the subject is on the study treatment and must agree to not become pregnant during 30 days after the last dose of the study drug.
•- Subject who are newly diagnosed or have diagnosis of relapsing mild to moderate UC. Diagnosis of UC originally must be established by sigmoidoscopy, colonoscopy, or barium enema and have compatible histology.
•- Subjects who, in the investigator's opinion are not likely to respond to 5-ASA doses of 2.4 g/day should not be included.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•-Severe UC according to the Physicians Global Asswssmant or subjects that have been in relapse for >6 weeks prior baselina.
•- Subjects who have relapsed on maintenance therapy with doses of 5-ASA>2g/day.
•If a subject had a recent 5-ASA dose reduction from >2g/day to <2g/day relapses within 2 weeks of thatv dose reduction, the subject will not be eligible .
•- Cron's Disease, proctitis, bleeding disorder, or active ulcer disease.
•-Subjects with Asthma if they are known to be 5-ASA sensitive.
•-Subjects who in the opinion of the investigator are at immediate or significant risk of toxic megacolon.¨
•-Previous colon surgary.
•- Subjects with moderate or severe renal impairment (defined as a creatinine level of >2 mg/dl) are contra-indicated for the treatment with 5-ASA compounds

发起方

Shire Pharmaceutical Development Inc